RT Journal Article
SR Electronic
T1 Intra-arterial tenecteplase after successful endovascular therapy (ANGEL-TNK): protocol of a multicentre, open-label, blinded end-point, prospective, randomised trial
JF Stroke and Vascular Neurology
JO Stroke Vasc Neurol
FD BMJ Publishing Group Ltd
SP svn-2024-003318
DO 10.1136/svn-2024-003318
A1 Huo, Xiaochuan
A1 Luo, Gang
A1 Sun, Dapeng
A1 Nguyen, Thanh
A1 Abdalkader, Mohamad
A1 Chen, Wenhuo
A1 Yao, Xiaoxi
A1 Yuan, Guangxiong
A1 Yi, Tingyu
A1 Han, Hongxin
A1 Pan, Yuesong
A1 Jovin, Tudor G
A1 Liebeskind, David S
A1 Liu, Liping
A1 Zhao, Xingquan
A1 Ren, Zeguang
A1 Wang, Yilong
A1 Wang, Yongjun
A1 Yan, Bernard
A1 Miao, Zhongrong
YR 2024
UL http://svn.bmj.com/content/early/2024/10/17/svn-2024-003318.abstract
AB Background Despite successful reperfusion after thrombectomy for large vessel occlusion (LVO) stroke, up to half of patients are dependent or dead at 3-month follow-up.The aim of the current study is to demonstrate safety and efficacy of administering adjunct intra-arterial (IA) tenecteplase in anterior circulation LVO patients who have achieved successful reperfusion defined as eTICI 2b50 to 3.Methods ANGEL-TNK is a multicentre, open-label, assessor-blinded endpoint, prospective randomised, controlled trial that will enrol up to 256 patients. Patients who meet inclusion criteria with anterior circulation LVO stroke and successful reperfusion will be randomised to receive IA tenecteplase or best medical management at 1:1 ratio.Results The primary endpoint is a 90-day excellent outcome defined as modified Rankin Scale (mRS) 0–1. The primary safety endpoint is symptomatic intracranial haemorrhage within 48 hours from randomisation. Secondary endpoints include 90-day ordinal mRS, mRS 0–2, mRS 0–3, all-cause mortality and any intracranial haemorrhage.Conclusion In patients with anterior circulation LVO stroke, the ANGEL-TNK trial will inform whether adjunct IA tenecteplase administered after successful thrombectomy reperfusion improves patient outcomes.Trial registration number NCT05624190.Data are available upon reasonable request.